An Imperial College, London-led team of researchers has found that estrogen receptor-positive breast cancers harbor a transcriptionally distinct population of cells that are pushed into "sleeper mode" by hormone therapy, and may represent an intermediate stage to becoming fully drug resistant. Their studies suggested that when these cells reawaken perhaps decades later they are more likely to metastasize and cause secondary tumors.